A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

NCT02644668 | Completed Phase 2 Results DMC

• 1 other identifier: CY 5021
• Study Type: interventional
• Target: 70
• Locations: 2 countries
• Sites: 19

Brief Summary

This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal muscular atrophy (SMA).

Conditions

Spinal Muscular Atrophy

Keywords

Reldesemtiv

Outcome Measures

Primary Outcomes (10)

• Change From Baseline to Week 8 in Forced Vital Capacity (FVC)

  FVC was measured using a calibrated spirometer (in units of liters). Patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs).

  baseline and 8 weeks

• Change From Baseline to Week 8 in Maximum Inspiratory Pressure (MIP)

  MIP was measured (in units of cm H20) using a calibrated spirometer with an inspiratory pressure valve attached. For the test, patients were asked to inhale as forcefully as possible, to their maximum pressure.

  baseline and 8 weeks

• Change From Baseline to Week 8 in Maximum Expiratory Pressure (MEP)

  MEP was measured (in units of cm H20) using a calibrated spirometer with an exspiratory pressure valve attached. For the test, patients were asked to maximally inhale then perform a forced exhalation with as forcefully as possible.

  baseline and 8 weeks

• Muscle Strength Mega-Score at Week 8

  Muscle strength of 3 muscle groups (elbow flexion, knee extension, and shoulder abduction) were measured bilaterally using a hand-held dynamometer. Muscle strength was measured twice for each body location; if the variability between the 2 measures was \> 15%, a third measure was obtained. The maximum muscle strength of the 2 measurements was identified and transformed as a percent change from baseline using the equation: (\[postbaseline value - baseline value\] / baseline value) × 100. The mega-score was a composite score that averaged strength across the 3 muscle groups. It was calculated as the mean of the non-missing transformed muscle strength scores among the 3 muscle groups each measure bilaterally (totaling 6 body locations).

  baseline and 8 weeks

• Change From Baseline to Week 8 in the Hammersmith Functional Motor Scale-Expanded (HFMS-E)

  The HFMS-E evaluated the level of independent mobility and motor skills through assessment of 33 test-items, each scored from 0 (worse) to 2 (better). The total score was calculated as the sum of the scores among the 33 test items, and has a range from 0 to 66.

  baseline and 8 weeks

• Change From Baseline to Week 8 in Revised Upper Limb Module (RULM)

  The RULM assessed motor function in the upper limbs (specifically shoulder, elbow, wrist, and hand function) that related to activities of everyday life. The RULM consisted of 20 items, 1 of which was scored on a 7-point scale (from 0 to 6), 18 were scored on a 3-point scale (from 0 to 2), and 1 was scored on a 2-point scale (0 or 1). The total score was the sum of each response and could range from a minimum of 0 to a maximum of 43 points. Higher scores reflected better motor function.

  baseline and 8 weeks

• Change From Baseline to Week 8 in the TUG Test

  The TUG test measured the time (in seconds) it took for a patient to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down.

  baseline and 8 weeks

• Change From Baseline to Week 8 in the 6MWT

  The 6MWT measured the distance (in meters) a patient walked in 6 minutes.

  baseline and 8 weeks

• Patient Global Assessment at the End of Week 8

  Patients assessed whether they felt the same, better, or worse than prior to dosing on Day 1.

  8 weeks

• Investigator Global Assessment at the End of Week 8

  The Investigator assessed whether patient appeared the same, better, or worse than prior to dosing on Day 1.

  8 weeks

Secondary Outcomes (2)

• Reldesemtiv Maximum Observed Plasma Concentration (Cmax)

  End of Week 8

• Reldesemtiv Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC0-12)

  End of Week 8

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Patients randomized to this treatment arm will receive a placebo suspension twice daily for 8 weeks.

Drug: Placebo

Reldesemtiv 150 mg twice daily

EXPERIMENTAL

Patient randomized to this treatment arm will receive reldesemtiv suspension at a dose of 150 mg, twice daily for 8 weeks.

Drug: Reldesemtiv 150 mg

Reldesemtiv 450 mg twice daily

EXPERIMENTAL

Patients randomized to this treatment arm will receive reldesemtiv suspension at a dose of 450 mg, twice daily for 8 weeks.

Drug: Reldesemtiv 450 mg

Interventions

Placebo DRUG

Granules for oral suspension (placebo)

Placebo

Reldesemtiv 150 mg DRUG

Granules for oral suspension, 18.7% reldesemtiv

Also known as: CK-2127107

Reldesemtiv 150 mg twice daily

Reldesemtiv 450 mg DRUG

Granules for oral suspension, 56.0% reldesemtiv

Also known as: CK-2127107

Reldesemtiv 450 mg twice daily

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to comprehend and willing to sign an Informed Consent Form (ICF) for patients 18 years of age and older. For patients less than 18 years of age, parent(s)/legal guardian(s) of patients must provide written informed consent prior to participation in the study and informed assent will be obtained from minors at least 12 years of age when required by regulation.
• Males or females with genetically confirmed diagnosis of SMA who are Type II, III or IV and at least 12 years of age
• Ambulatory patients, once having achieved a standing position independently, must be able to complete at least one lap in the 6-minute walk test (at least 50 meters) within 6 minutes without assistance.
• Non-ambulatory patients (defined as individuals who are effectively requiring a wheelchair for all mobility needs; they may be able to stand or walk short distances, but unable to walk 50 meters without assistance in 6 minutes). Non-ambulatory patients must be able to tolerate an upright sitting position, with support, continuously for 3 hours
• Hammersmith (HFMS-E) score ≥ 10 and ≤ 54
• Contracture of the elbow flexion and knee flexion ≤ 90 degrees
• Pre-study clinical laboratory findings within the normal range or, if outside the normal range, deemed not clinically significant by the Investigator
• Able to swallow an oral suspension and in the opinion of the Investigator, is expected to continue to be able to do so for the duration of the trial. Administration via a feeding tube is not allowed.
• Forced vital capacity (FVC) \> 20% predicted
• Male patients who have reached puberty must agree to do either of the following from Screening until 10 weeks after the last dose of the investigational product unless they have had a vasectomy and confirmed sperm count is zero:
• Abstain from sexual intercourse, OR
• If having heterosexual intercourse, must use a condom and their female partners who are of childbearing potential must use a highly effective contraception method\*
• Female patients who have had their first period will be considered of childbearing potential unless they are anatomically and physiologically incapable of becoming pregnant. If of childbearing potential, the female patients must:
• Have a negative urine/serum pregnancy test at Screening AND
• Abstain from heterosexual intercourse from Screening until 10 weeks after the last dose of investigational product OR

You may not qualify if:

• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator
• Hospitalization within 2 months of Screening
• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy will be allowed)
• A clinically significant illness within 4 weeks of Screening
• History of alcoholism or drug addiction within 2 years prior to Screening
• History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to Screening
• Patient has used a strong CYP3A4 inhibitor within 7 days prior to first dose of study drug or a strong CYP3A4 inducer within 14 days prior to first dose of study drug
• Any other medical condition that would interfere with performance of testing including (but not limited to) significant joint pain or arthritis limiting mobility, and chronic neuromuscular pain sufficient to require ongoing analgesic medication
• Participation by two people at the same time that are living in the same household
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days or five half-lives of the other investigational study drug, whichever is greater, prior to Screening
• An ALT or AST greater than 2-fold the upper limit of normal (ULN) or has total bilirubin greater than the ULN at screening. These assessments may be repeated once at the investigator's discretion (within the screening window)
• Currently taking nusinersen, or has taken it in the past, or plans to take it during the course the study

Sponsors & Collaborators

• Cytokinetics: lead
• Astellas Pharma Global Development, Inc.: collaborator

Study Sites (19)

UCLA

Los Angeles, California, 90095, United States

Location

University of California Irvine

Orange, California, 92868, United States

Location

Pediatric Neuromuscular Clinic Stanford University

Palo Alto, California, 94304, United States

Location

Children's Hospital Colorado

Aurora, Colorado, 80045, United States

Location

Hospital for Special Care

New Britain, Connecticut, 06053, United States

Location

Nemours Childrens Hospital

Orlando, Florida, 32827, United States

Location

Ann and Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States

Location

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

Johns Hopkins Hospital Institute for Clinical and Translational Research Pediatric Clinical Research Unit

Baltimore, Maryland, 21287, United States

Location

Boston Children's Hospital

Boston, Massachusetts, 02115, United States

Location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Duke University Medical Center

Durham, North Carolina, 27705, United States

Location

The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States

Location

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States

Location

The University of Utah, Clinical Neurosciences Center

Salt Lake City, Utah, 84132, United States

Location

Alberta Children's Hospital

Calgary, Alberta, T3B 6A8, Canada

Location

Children's and Women's Health Centre of British Columbia

Vancouver, British Columbia, V6H 3V4, Canada

Location

Children's Hospital - LHSC

London, Ontario, N6A 4G5, Canada

Location

Montreal Neurological Institute and Hospital

Montreal, Quebec, H3A 2B4, Canada

Location

MeSH Terms

Conditions

Muscular Atrophy, Spinal

Interventions

reldesemtiv

Condition Hierarchy (Ancestors)

Spinal Cord Diseases; Central Nervous System Diseases; Nervous System Diseases; Motor Neuron Disease; Neurodegenerative Diseases; Neuromuscular Diseases

Results Point of Contact

• Title: MD Cytokinetics
• Organization: Cytokinetics, Inc.

medicalaffairs@cytokinetics.com

650-624-2929

Study Officials

• MD, Cytokinetics

  Cytokinetics, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 23, 2015
• First Posted: January 1, 2016
• Study Start: January 14, 2016
• Primary Completion: May 31, 2018
• Study Completion: May 31, 2018
• Last Updated: August 31, 2020
• Results First Posted: August 31, 2020

Record last verified: 2020-08

Data Sharing

• IPD Sharing: Will not share

Locations

CA (4); US (15)